Terms: = Kidney tumors AND PRCC, Q92733, TPRC, RCCP1, MGC4723, MGC17178, ENSG00000143294, 5546 AND Treatment
109 results:
1. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
2. CT features based preoperative predictors of aggressive pathology for clinical T1 solid renal cell carcinoma and the development of nomogram model.
Wang K; Dong L; Li S; Liu Y; Niu Y; Li G
BMC Cancer; 2024 Jan; 24(1):148. PubMed ID: 38291357
[TBL] [Abstract] [Full Text] [Related]
3. Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC.
Hong SH; Lee YJ; Jang EB; Hwang HJ; Kim ES; Son DH; Park SY; Moon HS; Yoon YE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203388
[TBL] [Abstract] [Full Text] [Related]
4. ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K; Onder E
Pathol Res Pract; 2024 Jan; 253():154951. PubMed ID: 38039739
[TBL] [Abstract] [Full Text] [Related]
5. Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials.
Maughan BL; Sirohi D
Curr Treat Options Oncol; 2023 Sep; 24(9):1199-1212. PubMed ID: 37407886
[TBL] [Abstract] [Full Text] [Related]
6. Identification of basement membrane-related prognostic signature for predicting prognosis, immune response and potential drug prediction in papillary renal cell carcinoma.
Xi Y; Song L; Wang S; Zhou H; Ren J; Zhang R; Fu F; Yang Q; Duan G; Wang J
Math Biosci Eng; 2023 Apr; 20(6):10694-10724. PubMed ID: 37322956
[TBL] [Abstract] [Full Text] [Related]
7. Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic Targets.
Angori S; Banaei-Esfahani A; Mühlbauer K; Bolck HA; Kahraman A; Karakulak T; Poyet C; Feodoroff M; Potdar S; Kallioniemi O; Pietiäinen V; Schraml P; Moch H
Eur Urol Focus; 2023 Sep; 9(5):751-759. PubMed ID: 36933996
[TBL] [Abstract] [Full Text] [Related]
8. PCGF6/MAX/KDM5D facilitates MAZ/CDK4 axis expression and prcc progression by hypomethylation of the DNA promoter.
Zhu M; Zhang RN; Zhang H; Qu CB; Zhang XC; Ren LX; Yang Z; Gu JF
Epigenetics Chromatin; 2023 Mar; 16(1):9. PubMed ID: 36890610
[TBL] [Abstract] [Full Text] [Related]
9. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract] [Full Text] [Related]
10. Predictive characteristics for disease recurrence and overall survival in non-metastatic clinical T1 renal cell carcinoma - results from the National Swedish kidney Cancer Register.
Almdalal T; Karlsson Rosenblad A; Hellström M; Kjellman A; Lindblad P; Lundstam S; Sundqvist P; Ljungberg B
Scand J Urol; 2023; 57(1-6):67-74. PubMed ID: 36520023
[TBL] [Abstract] [Full Text] [Related]
11. Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma.
Zhang X; Liu X; Xiong R; An HX
Aging (Albany NY); 2022 Nov; 14(23):9599-9616. PubMed ID: 36385010
[TBL] [Abstract] [Full Text] [Related]
12. A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.
Hu Y; Xu S; Qi Q; Wang X; Meng J; Zhou J; Hao Z; Liang Q; Feng X; Liang C
Front Public Health; 2022; 10():989566. PubMed ID: 36276376
[TBL] [Abstract] [Full Text] [Related]
13. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging: Diagnostic Pathways and Metabolites for Renal Tumor Entities.
Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
Oncology; 2023; 101(2):126-133. PubMed ID: 36198279
[TBL] [Abstract] [Full Text] [Related]
14. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.
Sweeney PL; Jang A; Halat SK; Pal SK; Barata PC
Cancer Treat Res Commun; 2022; 33():100639. PubMed ID: 36162322
[TBL] [Abstract] [Full Text] [Related]
15. Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics.
Krencz I; Vetlényi E; Dankó T; Petővári G; Moldvai D; Sztankovics D; Raffay R; Mészáros K; Sebestyén E; Végső G; Pápay J; Sebestyén A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142502
[TBL] [Abstract] [Full Text] [Related]
16. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract] [Full Text] [Related]
17. Patient-derived renal cell carcinoma organoids for personalized cancer therapy.
Li Z; Xu H; Yu L; Wang J; Meng Q; Mei H; Cai Z; Chen W; Huang W
Clin Transl Med; 2022 Jul; 12(7):e970. PubMed ID: 35802820
[TBL] [Abstract] [Full Text] [Related]
18. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
[TBL] [Abstract] [Full Text] [Related]
20. Papillary renal cell carcinoma: current and controversial issues.
Angori S; Lobo J; Moch H
Curr Opin Urol; 2022 Jul; 32(4):344-351. PubMed ID: 35674688
[TBL] [Abstract] [Full Text] [Related]
[Next]
